LoginSignup
IQVIA Hldgs logo

IQVIA Hldgs

Stock
Stock
Ticker: IQV
IQV

Price

Price

CHART BY

Frequently asked questions

The market capitalization of IQVIA Hldgs is $44.46B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for IQVIA Hldgs is 33.50. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
IQVIA Hldgs's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $8.062. EPS indicates the company's profitability on a per-share basis.
Currently, 24 analysts cover IQVIA Hldgs's stock, with a consensus target price of $278.53. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, IQVIA Hldgs reported a revenue of $16.99B.
IQVIA Hldgs's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $3.55B. EBITDA measures the company's overall financial performance.
IQVIA Hldgs has a free cash flow of $2.18B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
IQVIA Hldgs employs approximately 93,000 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of IQVIA Hldgs is 162.95M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$44.46B
EPS (TTM) 
$8.062
Free Float 
162.95M
P/E ratio (TTM) 
33.50
Revenue (TTM) 
$16.99B
EBITDA (TTM) 
$3.55B
Free Cashflow (TTM) 
$2.18B

Pricing

1D span
$264.92$271.28
52W span
$154.50$277.03

Analyst Ratings

The price target is $278.53 and the stock is covered by 24 analysts.

Buy

19

Hold

5

Sell

0

Information

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission-critical information, technology solutions, and real-world evidence services to the company's life sciences clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial-related services. The Contract Sales and Medical Solutions segment offers healthcare provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1950 and is headquartered in Durham, NC.

Employees
93,000
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
IQV

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin